Toronto, Ontario–(Newsfile Corp. – January 19, 2023) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma Bright” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has signed a SPA (Share Purchase Agreement) with Inretio Ltd. (“Inretio”) for its innovative protective blood clot retriever technology. Therma Bright has the right to invest up to USD $2,000,000 in cash and USD $500,000 in Therma Bright shares to earn up to 25% in Inretio Inc., subject to TSX Venture Exchange approval. The cash and shares are payable, at Therma’s option, upon certain milestones being achieved by Inretio over time by the end of May 31, 2024. Therma Bright has made the first payment to Inretio totaling USD $200,000.
Inretio is developing a medical device called PREVA™ to treat ischemic stroke. The PREVA™ clot retriever is a groundbreaking medical device that will change the way ischemic strokes are treated. It is the first and only protective clot retriever that uses a distal basket. The device’s unique PREVA™ basket “ensnares” the clot, encapsulating it and protecting the brain from any sub-clots breaking off during the thrombectomy procedure. This ensures the complete removal of the clot and its fragments, leading to more successful revascularization of the brain which can prevent further damage and complications. The PREVA™ clot retriever is a game-changing technology that has the potential to significantly improve outcomes of clot removal procedures for stroke patients.
The PREVA™ device was developed by Raviv Vine and his team of engineers & researchers at Inretio. Mr. Vine has over 25 years of experience working at the nanoscale level developing semiconductor fabrication plants in the United States and Israel for Intel Inc. Due to a personal friend’s loss of a loved one to stroke, it was only natural that Mr. Vine was called upon to develop PREVA™ with his advanced knowledge of nano-scale technology and working with specialized materials.
As published by The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00163-X/fulltext) the existing clot retriever technology is currently 50% effective at retrieving blood clots in the human brain. Early animal trials with PREVA™ indicate the technology can achieve 80% success rate. Inretio will look to repeat the same success with PREVA™ in clinical trials during 2023. Inretio has received an investment from the Israel Innovation Authority to reach full development of the technology and a working prototype to complete these animal studies in the USA and Israel. Further, Inretio has secured its IP portfolio with plans to expand the IP with additional novel features for the PREVA™ device. All manufacturing is completed in Israel with the ability to ramp production to meet demand.
Inretio’s plans for 2023 include additional animal studies until March 2023 and clinical trials by July 2023 at locations around the world including Israel, Canada and the US at renowned hospitals.
The current marketplace for clot retrievers is dominated by major US medical device companies. The current market is valued at USD $2.83 billion in 2022 and expected to grow to USD 4.51 billion in 2030, a 6% CAGR over that time period. As the population ages, the incidence of strokes is projected to increase, with the World Health Organization estimating that by 2035, stroke will be the second leading cause of death worldwide. The PREVA™ device has the potential to make a real impact by saving lives and improving health outcomes for those who suffer from ischemic stroke.
Overall, the PREVA device represents a significant advancement in the field of stroke care. It has the potential to save lives and improve health outcomes for those who suffer from ischemic stroke by providing a safer, more effective, and faster treatment option. By using this device, it could provide better recovery and reduce the number of re-hospitalizations, leading to cost savings for the healthcare system.
Rob Fia, CEO commented: “When I first met Raviv and his team I was instantly impressed and intrigued at how quickly he and his team were able to develop the PREVA™ device to treat ischemic blood clots. Inretio’s technology is a complementary fit for Therma Bright and our preventative blood clot technology Venowave, and our ability to assist Inretio to take the PREVA™ technology forward. Therma Bright is pleased to reach this agreement with Inretio based on an attractive valuation and the size of the market. This agreement is a win-win for Inretio and Therma Bright. It is expected that Inretio’s technology will become a part of neurosurgeons’ toolbox and secure a significant portion of the neurovascular device market in the future. Therma Bright, with the help of Inretio’s small yet talented team, will be able to set a dominant footprint in the neurovascular device market.”
The Company would also like to announce that it has engaged Reinvent Business to execute a market and brand awareness campaign. This campaign will run over a 12-month period paid in cash for USD $25,000, subject to TSXV approval. The Company has also retained the services of Aktiencheck.de AG to provide editorial write-ups, public relations, brand awareness, and digital marketing services to the Company for the European market for the next two quarters, subject to TSXV approval. Aktienceck.de AG has been paid consideration of €50,000.
About Inretio Inc.
Inretio, an Israeli medical device start-up, is revolutionizing the treatment of ischemic stroke with their innovative approach to clot-retrieving devices. Ischemic strokes, which are caused by a clot blocking blood flow to the brain, afflict over 690,000 patients in the US each year, according to the CDC, with current devices providing an incomplete solution. Inretio’s concept for clot-retrieval aims to improve effectiveness and prevent complications during thrombectomy procedures, ultimately elevating outcomes for stroke patients. This cutting-edge technology has the potential to greatly impact the lives of those affected by ischemic strokes and make a significant difference in the medical community.
About Therma Bright Inc.
Therma Bright, developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today’s most important medical and healthcare challenges. The Company’s initial breakthrough proprietary technology delivers effective, non-invasive, and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the U.S. FDA in 1997. Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute “forward-looking” statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation. as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/151859
Related Quotes
The S&P 500 dipped by 19% in 2022, but stocks still don’t seem cheap to Charlie Munger, Warren Buffett’s billionaire partner at Berkshire Hathaway. “In my whole adult life, I have never hoarded cash, waiting for better conditions,” Munger said in an interview in late 2022. “I’ve just invested in the best thing I could find.” Yet he acknowledged that Berkshire Hathaway is sitting on billions of dollars in cash. The reason isn’t that Buffett and Munger think they can wait for stocks to get even ch
Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.
Her Ark funds have snagged 806,663 Tesla shares in January alone, recently valued at $105.4 million.
There are financial technology companies that are bringing innovation to consumers, but tougher credit markets have hurt their businesses. This could be an opportunity for long-term investors; these three stocks are poised to flourish when economic conditions ease up, so consider them before the bear market ends. Rapidly rising interest rates created two problems for Upstart Holdings (NASDAQ: UPST), which uses artificial intelligence to replace the traditional FICO credit score in approving consumer loans.
Yahoo Finance Live anchors Seana Smith and Dave Briggs look ahead to the tech stock earnings due out next week.
In this article, we discuss 12 hot penny stocks on the rise. If you want to see more stocks in this selection, check out 5 Hot Penny Stocks On the Rise. Penny stocks usually trade under $5 and are favored by new investors or market participants who prefer day trading. Some key indicators that penny […]
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Citigroup is planning to sell the consumer banking and middle-market operations of Citibanamex, an important part of its transformation.
Lundin Mining's (TSE:LUN) stock is up by a considerable 32% over the past three months. Given that the market rewards…
Investors have turned their attention to profits and cash flow as interest rates have risen. Does that give the edge to PayPal (NASDAQ: PYPL) stock or to SoFi (NASDAQ: SOFI) stock? This video will answer that question, so tune in to find out.
Lately, growth stocks have taken it on the chin. Despite macroeconomic headwinds, many growth stocks are fantastic businesses that will continue to impress for years to come. Let's take a look at three growth stocks that are poised for bull runs in 2023: Advanced Micro Devices (NASDAQ: AMD), Cloudflare,(NYSE: NET) and Airbnb (NASDAQ: ABNB).
Shares of Scilex Holding (NASDAQ: SCLX) were up 39.7% this week as of Thursday, according to data provided by S&P Global Market Intelligence. Scilex develops non-opioid treatments for acute and chronic pain. The healthcare company is majority owned by Sorrento Therapeutics, and there have been rumors of a potential buyout.
The latest update from an industry darling could signal big financial challenges for marijuana companies.
Our call of the day from TheoTrade's Professor Jeff Bierman warns that the next group of stocks to come under pressure will be consumer staples.
Markets remain volatile as 2023 gets into full swing, with a strong two-week gain followed by several days of losses. The headwinds remain the obvious: inflation, though moderating, remains high, and the Federal Reserve remains committed to battling the surge in prices, even at risk of a recession. On the other hand, stocks found support from a general improvement in sentiment, as investors believe that the downward trend in inflation rates may be here to stay. So the market landscape presents s
Buy cheap? Even in the stock market, buyers like to find a bargain. Defining a bargain, however, can be tricky. There’s a stigma that gets attached to low stock prices, based on the reality that most stocks don’t fall without a reason. And those reasons are usually rooted in some facet of poor company performance. But not always, and that’s why finding stock bargains can be tricky. There are plenty of low-priced equities out there with sound fundamentals and solid future prospects, and these opt
Quarterly results suggest that some of the fears investors had about the lender's business were overblown.
Healthcare stocks that struggled last year could be in for some relief. Now that there's less upheaval due to the pandemic, hospitals are resuming more normal operations, and that may mean better financial results — and potentially better returns for healthcare investors this year. An encouraging development suggests that brighter days could be ahead for stocks with exposure to hospitals, including Medical Properties Trust (NYSE: MPW) and HCA Healthcare (NYSE: HCA).
(Bloomberg) — Hours after revealing a scandal that would roil Brazilian markets, Sergio Rial joined a Zoom call with hundreds of panicked investors. It was an attempt to explain the $4 billion accounting gap that pushed him to quit his new job at the helm of retailer Americanas SA.Most Read from BloombergHolmes Belongs in Prison, Not $13,000-a-Month Manor, US SaysGoogle to Cut 12,000 Jobs in 6% Reduction of Global WorkforceMore Young Americans Are Dying, But Not From VaccinesTreasury Taps Retir
Nio (NYSE: NIO) shares jumped more than 5% Friday morning and were holding on to a gain of 3% as of 2:33 p.m. ET. Nio — like other Chinese automakers — has been hit by multiple rounds of business slowdowns due to COVID-19-related shutdowns and drops in consumer demand over the past year. The slump in EV demand has led to vehicle price drops by EV leader Tesla in China that were followed by cuts from other domestic EV makers.
